https://compoundevidence.com/syntheses/glp1-obesity-weight-change/2025-05-23 https://compoundevidence.com/syntheses/glp1-obesity-weight-change/search-strategy/2025-05-23 https://compoundevidence.com/syntheses/glp1-obesity-weight-change/included-studies/2025-05-23 https://compoundevidence.com/syntheses/glp1-obesity-weight-change/summary-of-findings/2025-05-23 https://compoundevidence.com/syntheses/glp1-obesity-weight-change/amendments/2025-05-23 https://compoundevidence.com/syntheses/dual-vs-single-agonist-weight/2026-08-19 https://compoundevidence.com/syntheses/dual-vs-single-agonist-weight/search-strategy/2026-08-19 https://compoundevidence.com/syntheses/dual-vs-single-agonist-weight/included-studies/2026-08-19 https://compoundevidence.com/syntheses/dual-vs-single-agonist-weight/summary-of-findings/2026-08-19 https://compoundevidence.com/syntheses/dual-vs-single-agonist-weight/amendments/2026-08-19 https://compoundevidence.com/syntheses/incretin-cardiovascular-outcomes/2025-10-24 https://compoundevidence.com/syntheses/incretin-cardiovascular-outcomes/search-strategy/2025-10-24 https://compoundevidence.com/syntheses/incretin-cardiovascular-outcomes/included-studies/2025-10-24 https://compoundevidence.com/syntheses/incretin-cardiovascular-outcomes/summary-of-findings/2025-10-24 https://compoundevidence.com/syntheses/incretin-cardiovascular-outcomes/amendments/2025-10-24 https://compoundevidence.com/syntheses/weight-regain-after-discontinuation/2026-03-09 https://compoundevidence.com/syntheses/weight-regain-after-discontinuation/search-strategy/2026-03-09 https://compoundevidence.com/syntheses/weight-regain-after-discontinuation/included-studies/2026-03-09 https://compoundevidence.com/syntheses/weight-regain-after-discontinuation/summary-of-findings/2026-03-09 https://compoundevidence.com/syntheses/weight-regain-after-discontinuation/amendments/2026-03-09 https://compoundevidence.com/syntheses/gastrointestinal-tolerability-incretins/2025-10-12 https://compoundevidence.com/syntheses/gastrointestinal-tolerability-incretins/search-strategy/2025-10-12 https://compoundevidence.com/syntheses/gastrointestinal-tolerability-incretins/included-studies/2025-10-12 https://compoundevidence.com/syntheses/gastrointestinal-tolerability-incretins/summary-of-findings/2025-10-12 https://compoundevidence.com/syntheses/gastrointestinal-tolerability-incretins/amendments/2025-10-12 https://compoundevidence.com/syntheses/lean-mass-loss-incretins/2025-03-17 https://compoundevidence.com/syntheses/lean-mass-loss-incretins/search-strategy/2025-03-17 https://compoundevidence.com/syntheses/lean-mass-loss-incretins/included-studies/2025-03-17 https://compoundevidence.com/syntheses/lean-mass-loss-incretins/summary-of-findings/2025-03-17 https://compoundevidence.com/syntheses/lean-mass-loss-incretins/amendments/2025-03-17 https://compoundevidence.com/syntheses/oral-vs-injectable-glp1/2025-07-16 https://compoundevidence.com/syntheses/oral-vs-injectable-glp1/search-strategy/2025-07-16 https://compoundevidence.com/syntheses/oral-vs-injectable-glp1/included-studies/2025-07-16 https://compoundevidence.com/syntheses/oral-vs-injectable-glp1/summary-of-findings/2025-07-16 https://compoundevidence.com/syntheses/oral-vs-injectable-glp1/amendments/2025-07-16 https://compoundevidence.com/syntheses/renal-outcomes-incretins/2026-05-07 https://compoundevidence.com/syntheses/renal-outcomes-incretins/search-strategy/2026-05-07 https://compoundevidence.com/syntheses/renal-outcomes-incretins/included-studies/2026-05-07 https://compoundevidence.com/syntheses/renal-outcomes-incretins/summary-of-findings/2026-05-07 https://compoundevidence.com/syntheses/renal-outcomes-incretins/amendments/2026-05-07 https://compoundevidence.com/syntheses/hfpef-incretins/2024-10-11 https://compoundevidence.com/syntheses/hfpef-incretins/search-strategy/2024-10-11 https://compoundevidence.com/syntheses/hfpef-incretins/included-studies/2024-10-11 https://compoundevidence.com/syntheses/hfpef-incretins/summary-of-findings/2024-10-11 https://compoundevidence.com/syntheses/hfpef-incretins/amendments/2024-10-11 https://compoundevidence.com/syntheses/mash-histological-endpoints/2026-01-12 https://compoundevidence.com/syntheses/mash-histological-endpoints/search-strategy/2026-01-12 https://compoundevidence.com/syntheses/mash-histological-endpoints/included-studies/2026-01-12 https://compoundevidence.com/syntheses/mash-histological-endpoints/summary-of-findings/2026-01-12 https://compoundevidence.com/syntheses/mash-histological-endpoints/amendments/2026-01-12 https://compoundevidence.com/syntheses/sleep-apnoea-weight-agents/2026-02-25 https://compoundevidence.com/syntheses/sleep-apnoea-weight-agents/search-strategy/2026-02-25 https://compoundevidence.com/syntheses/sleep-apnoea-weight-agents/included-studies/2026-02-25 https://compoundevidence.com/syntheses/sleep-apnoea-weight-agents/summary-of-findings/2026-02-25 https://compoundevidence.com/syntheses/sleep-apnoea-weight-agents/amendments/2026-02-25 https://compoundevidence.com/syntheses/coa-completeness-research-supply/2025-05-20 https://compoundevidence.com/syntheses/coa-completeness-research-supply/search-strategy/2025-05-20 https://compoundevidence.com/syntheses/coa-completeness-research-supply/included-studies/2025-05-20 https://compoundevidence.com/syntheses/coa-completeness-research-supply/summary-of-findings/2025-05-20 https://compoundevidence.com/syntheses/coa-completeness-research-supply/amendments/2025-05-20 https://compoundevidence.com/syntheses/counterion-content-underreporting/2026-09-01 https://compoundevidence.com/syntheses/counterion-content-underreporting/search-strategy/2026-09-01 https://compoundevidence.com/syntheses/counterion-content-underreporting/included-studies/2026-09-01 https://compoundevidence.com/syntheses/counterion-content-underreporting/summary-of-findings/2026-09-01 https://compoundevidence.com/syntheses/counterion-content-underreporting/amendments/2026-09-01 https://compoundevidence.com/syntheses/bpc-157-human-evidence/2026-07-03 https://compoundevidence.com/syntheses/bpc-157-human-evidence/search-strategy/2026-07-03 https://compoundevidence.com/syntheses/bpc-157-human-evidence/included-studies/2026-07-03 https://compoundevidence.com/syntheses/bpc-157-human-evidence/summary-of-findings/2026-07-03 https://compoundevidence.com/syntheses/bpc-157-human-evidence/amendments/2026-07-03 https://compoundevidence.com/syntheses/peptide-supply-quality-analytical-surveys/2026-08-31 https://compoundevidence.com/syntheses/peptide-supply-quality-analytical-surveys/search-strategy/2026-08-31 https://compoundevidence.com/syntheses/peptide-supply-quality-analytical-surveys/included-studies/2026-08-31 https://compoundevidence.com/syntheses/peptide-supply-quality-analytical-surveys/summary-of-findings/2026-08-31 https://compoundevidence.com/syntheses/peptide-supply-quality-analytical-surveys/amendments/2026-08-31 https://compoundevidence.com/syntheses/gh-secretagogue-clinical-evidence/2025-05-26 https://compoundevidence.com/syntheses/gh-secretagogue-clinical-evidence/search-strategy/2025-05-26 https://compoundevidence.com/syntheses/gh-secretagogue-clinical-evidence/included-studies/2025-05-26 https://compoundevidence.com/syntheses/gh-secretagogue-clinical-evidence/summary-of-findings/2025-05-26 https://compoundevidence.com/syntheses/gh-secretagogue-clinical-evidence/amendments/2025-05-26 https://compoundevidence.com/syntheses/russian-registered-neuropeptides/2026-05-13 https://compoundevidence.com/syntheses/russian-registered-neuropeptides/search-strategy/2026-05-13 https://compoundevidence.com/syntheses/russian-registered-neuropeptides/included-studies/2026-05-13 https://compoundevidence.com/syntheses/russian-registered-neuropeptides/summary-of-findings/2026-05-13 https://compoundevidence.com/syntheses/russian-registered-neuropeptides/amendments/2026-05-13 https://compoundevidence.com/syntheses/sponsor-conducted-evidence-base/2025-04-11 https://compoundevidence.com/syntheses/sponsor-conducted-evidence-base/search-strategy/2025-04-11 https://compoundevidence.com/syntheses/sponsor-conducted-evidence-base/included-studies/2025-04-11 https://compoundevidence.com/syntheses/sponsor-conducted-evidence-base/summary-of-findings/2025-04-11 https://compoundevidence.com/syntheses/sponsor-conducted-evidence-base/amendments/2025-04-11 https://compoundevidence.com/syntheses/surrogate-outcomes-in-obesity/2026-01-26 https://compoundevidence.com/syntheses/surrogate-outcomes-in-obesity/search-strategy/2026-01-26 https://compoundevidence.com/syntheses/surrogate-outcomes-in-obesity/included-studies/2026-01-26 https://compoundevidence.com/syntheses/surrogate-outcomes-in-obesity/summary-of-findings/2026-01-26 https://compoundevidence.com/syntheses/surrogate-outcomes-in-obesity/amendments/2026-01-26 https://compoundevidence.com/syntheses/adolescent-incretin-evidence/2026-01-09 https://compoundevidence.com/syntheses/adolescent-incretin-evidence/search-strategy/2026-01-09 https://compoundevidence.com/syntheses/adolescent-incretin-evidence/included-studies/2026-01-09 https://compoundevidence.com/syntheses/adolescent-incretin-evidence/summary-of-findings/2026-01-09 https://compoundevidence.com/syntheses/adolescent-incretin-evidence/amendments/2026-01-09 https://compoundevidence.com/syntheses/thyroid-c-cell-signal/2024-08-23 https://compoundevidence.com/syntheses/thyroid-c-cell-signal/search-strategy/2024-08-23 https://compoundevidence.com/syntheses/thyroid-c-cell-signal/included-studies/2024-08-23 https://compoundevidence.com/syntheses/thyroid-c-cell-signal/summary-of-findings/2024-08-23 https://compoundevidence.com/syntheses/thyroid-c-cell-signal/amendments/2024-08-23 https://compoundevidence.com/syntheses/amylin-analogue-evidence/2026-08-10 https://compoundevidence.com/syntheses/amylin-analogue-evidence/search-strategy/2026-08-10 https://compoundevidence.com/syntheses/amylin-analogue-evidence/included-studies/2026-08-10 https://compoundevidence.com/syntheses/amylin-analogue-evidence/summary-of-findings/2026-08-10 https://compoundevidence.com/syntheses/amylin-analogue-evidence/amendments/2026-08-10 https://compoundevidence.com/syntheses/discontinued-programmes-as-evidence/2024-09-09 https://compoundevidence.com/syntheses/discontinued-programmes-as-evidence/search-strategy/2024-09-09 https://compoundevidence.com/syntheses/discontinued-programmes-as-evidence/included-studies/2024-09-09 https://compoundevidence.com/syntheses/discontinued-programmes-as-evidence/summary-of-findings/2024-09-09 https://compoundevidence.com/syntheses/discontinued-programmes-as-evidence/amendments/2024-09-09 https://compoundevidence.com/syntheses/reconstitution-practice-and-content/2024-11-05 https://compoundevidence.com/syntheses/reconstitution-practice-and-content/search-strategy/2024-11-05 https://compoundevidence.com/syntheses/reconstitution-practice-and-content/included-studies/2024-11-05 https://compoundevidence.com/syntheses/reconstitution-practice-and-content/summary-of-findings/2024-11-05 https://compoundevidence.com/syntheses/reconstitution-practice-and-content/amendments/2024-11-05 https://compoundevidence.com/syntheses/pancreatitis-risk-incretins/2026-03-22 https://compoundevidence.com/syntheses/pancreatitis-risk-incretins/search-strategy/2026-03-22 https://compoundevidence.com/syntheses/pancreatitis-risk-incretins/included-studies/2026-03-22 https://compoundevidence.com/syntheses/pancreatitis-risk-incretins/summary-of-findings/2026-03-22 https://compoundevidence.com/syntheses/pancreatitis-risk-incretins/amendments/2026-03-22 https://compoundevidence.com/syntheses/gastroparesis-and-anaesthesia/2025-02-13 https://compoundevidence.com/syntheses/gastroparesis-and-anaesthesia/search-strategy/2025-02-13 https://compoundevidence.com/syntheses/gastroparesis-and-anaesthesia/included-studies/2025-02-13 https://compoundevidence.com/syntheses/gastroparesis-and-anaesthesia/summary-of-findings/2025-02-13 https://compoundevidence.com/syntheses/gastroparesis-and-anaesthesia/amendments/2025-02-13 https://compoundevidence.com/syntheses/endotoxin-in-research-supply/2026-02-05 https://compoundevidence.com/syntheses/endotoxin-in-research-supply/search-strategy/2026-02-05 https://compoundevidence.com/syntheses/endotoxin-in-research-supply/included-studies/2026-02-05 https://compoundevidence.com/syntheses/endotoxin-in-research-supply/summary-of-findings/2026-02-05 https://compoundevidence.com/syntheses/endotoxin-in-research-supply/amendments/2026-02-05 https://compoundevidence.com/syntheses/primary-vs-secondary-prevention-cv/2026-04-08 https://compoundevidence.com/syntheses/primary-vs-secondary-prevention-cv/search-strategy/2026-04-08 https://compoundevidence.com/syntheses/primary-vs-secondary-prevention-cv/included-studies/2026-04-08 https://compoundevidence.com/syntheses/primary-vs-secondary-prevention-cv/summary-of-findings/2026-04-08 https://compoundevidence.com/syntheses/primary-vs-secondary-prevention-cv/amendments/2026-04-08 https://compoundevidence.com/syntheses/tirzepatide-vs-semaglutide-t2d/2025-04-26 https://compoundevidence.com/syntheses/tirzepatide-vs-semaglutide-t2d/search-strategy/2025-04-26 https://compoundevidence.com/syntheses/tirzepatide-vs-semaglutide-t2d/included-studies/2025-04-26 https://compoundevidence.com/syntheses/tirzepatide-vs-semaglutide-t2d/summary-of-findings/2025-04-26 https://compoundevidence.com/syntheses/tirzepatide-vs-semaglutide-t2d/amendments/2025-04-26 https://compoundevidence.com/syntheses/peptide-purity-method-dependence/2026-05-20 https://compoundevidence.com/syntheses/peptide-purity-method-dependence/search-strategy/2026-05-20 https://compoundevidence.com/syntheses/peptide-purity-method-dependence/included-studies/2026-05-20 https://compoundevidence.com/syntheses/peptide-purity-method-dependence/summary-of-findings/2026-05-20 https://compoundevidence.com/syntheses/peptide-purity-method-dependence/amendments/2026-05-20 https://compoundevidence.com/syntheses/melanocortin-agonist-evidence/2024-10-16 https://compoundevidence.com/syntheses/melanocortin-agonist-evidence/search-strategy/2024-10-16 https://compoundevidence.com/syntheses/melanocortin-agonist-evidence/included-studies/2024-10-16 https://compoundevidence.com/syntheses/melanocortin-agonist-evidence/summary-of-findings/2024-10-16 https://compoundevidence.com/syntheses/melanocortin-agonist-evidence/amendments/2024-10-16 https://compoundevidence.com/syntheses/mitochondrial-peptide-evidence/2025-07-25 https://compoundevidence.com/syntheses/mitochondrial-peptide-evidence/search-strategy/2025-07-25 https://compoundevidence.com/syntheses/mitochondrial-peptide-evidence/included-studies/2025-07-25 https://compoundevidence.com/syntheses/mitochondrial-peptide-evidence/summary-of-findings/2025-07-25 https://compoundevidence.com/syntheses/mitochondrial-peptide-evidence/amendments/2025-07-25 https://compoundevidence.com/syntheses/thymic-peptide-immune-evidence/2025-06-17 https://compoundevidence.com/syntheses/thymic-peptide-immune-evidence/search-strategy/2025-06-17 https://compoundevidence.com/syntheses/thymic-peptide-immune-evidence/included-studies/2025-06-17 https://compoundevidence.com/syntheses/thymic-peptide-immune-evidence/summary-of-findings/2025-06-17 https://compoundevidence.com/syntheses/thymic-peptide-immune-evidence/amendments/2025-06-17 https://compoundevidence.com/syntheses/peptide-stability-in-use/2025-01-23 https://compoundevidence.com/syntheses/peptide-stability-in-use/search-strategy/2025-01-23 https://compoundevidence.com/syntheses/peptide-stability-in-use/included-studies/2025-01-23 https://compoundevidence.com/syntheses/peptide-stability-in-use/summary-of-findings/2025-01-23 https://compoundevidence.com/syntheses/peptide-stability-in-use/amendments/2025-01-23 https://compoundevidence.com/syntheses/obesity-pharmacotherapy-access-equity/2025-03-05 https://compoundevidence.com/syntheses/obesity-pharmacotherapy-access-equity/search-strategy/2025-03-05 https://compoundevidence.com/syntheses/obesity-pharmacotherapy-access-equity/included-studies/2025-03-05 https://compoundevidence.com/syntheses/obesity-pharmacotherapy-access-equity/summary-of-findings/2025-03-05 https://compoundevidence.com/syntheses/obesity-pharmacotherapy-access-equity/amendments/2025-03-05 https://compoundevidence.com/syntheses/network-transitivity-incretins/2025-03-11 https://compoundevidence.com/syntheses/network-transitivity-incretins/search-strategy/2025-03-11 https://compoundevidence.com/syntheses/network-transitivity-incretins/included-studies/2025-03-11 https://compoundevidence.com/syntheses/network-transitivity-incretins/summary-of-findings/2025-03-11 https://compoundevidence.com/syntheses/network-transitivity-incretins/amendments/2025-03-11 https://compoundevidence.com/syntheses/tirzepatide-obesity-effect/2025-08-04 https://compoundevidence.com/syntheses/tirzepatide-obesity-effect/search-strategy/2025-08-04 https://compoundevidence.com/syntheses/tirzepatide-obesity-effect/included-studies/2025-08-04 https://compoundevidence.com/syntheses/tirzepatide-obesity-effect/summary-of-findings/2025-08-04 https://compoundevidence.com/syntheses/tirzepatide-obesity-effect/amendments/2025-08-04 https://compoundevidence.com/syntheses/semaglutide-obesity-effect/2025-10-22 https://compoundevidence.com/syntheses/semaglutide-obesity-effect/search-strategy/2025-10-22 https://compoundevidence.com/syntheses/semaglutide-obesity-effect/included-studies/2025-10-22 https://compoundevidence.com/syntheses/semaglutide-obesity-effect/summary-of-findings/2025-10-22 https://compoundevidence.com/syntheses/semaglutide-obesity-effect/amendments/2025-10-22 https://compoundevidence.com/syntheses/dulaglutide-t2dm-effect/2026-04-14 https://compoundevidence.com/syntheses/dulaglutide-t2dm-effect/search-strategy/2026-04-14 https://compoundevidence.com/syntheses/dulaglutide-t2dm-effect/included-studies/2026-04-14 https://compoundevidence.com/syntheses/dulaglutide-t2dm-effect/summary-of-findings/2026-04-14 https://compoundevidence.com/syntheses/dulaglutide-t2dm-effect/amendments/2026-04-14 https://compoundevidence.com/syntheses/semaglutide-t2dm-effect/2025-10-04 https://compoundevidence.com/syntheses/semaglutide-t2dm-effect/search-strategy/2025-10-04 https://compoundevidence.com/syntheses/semaglutide-t2dm-effect/included-studies/2025-10-04 https://compoundevidence.com/syntheses/semaglutide-t2dm-effect/summary-of-findings/2025-10-04 https://compoundevidence.com/syntheses/semaglutide-t2dm-effect/amendments/2025-10-04 https://compoundevidence.com/syntheses/tirzepatide-t2dm-effect/2026-06-02 https://compoundevidence.com/syntheses/tirzepatide-t2dm-effect/search-strategy/2026-06-02 https://compoundevidence.com/syntheses/tirzepatide-t2dm-effect/included-studies/2026-06-02 https://compoundevidence.com/syntheses/tirzepatide-t2dm-effect/summary-of-findings/2026-06-02 https://compoundevidence.com/syntheses/tirzepatide-t2dm-effect/amendments/2026-06-02 https://compoundevidence.com/syntheses/exenatide-t2dm-effect/2026-07-28 https://compoundevidence.com/syntheses/exenatide-t2dm-effect/search-strategy/2026-07-28 https://compoundevidence.com/syntheses/exenatide-t2dm-effect/included-studies/2026-07-28 https://compoundevidence.com/syntheses/exenatide-t2dm-effect/summary-of-findings/2026-07-28 https://compoundevidence.com/syntheses/exenatide-t2dm-effect/amendments/2026-07-28 https://compoundevidence.com/syntheses/retatrutide-obesity-effect/2025-05-17 https://compoundevidence.com/syntheses/retatrutide-obesity-effect/search-strategy/2025-05-17 https://compoundevidence.com/syntheses/retatrutide-obesity-effect/included-studies/2025-05-17 https://compoundevidence.com/syntheses/retatrutide-obesity-effect/summary-of-findings/2025-05-17 https://compoundevidence.com/syntheses/retatrutide-obesity-effect/amendments/2025-05-17 https://compoundevidence.com/syntheses/cagrisema-obesity-effect/2025-10-17 https://compoundevidence.com/syntheses/cagrisema-obesity-effect/search-strategy/2025-10-17 https://compoundevidence.com/syntheses/cagrisema-obesity-effect/included-studies/2025-10-17 https://compoundevidence.com/syntheses/cagrisema-obesity-effect/summary-of-findings/2025-10-17 https://compoundevidence.com/syntheses/cagrisema-obesity-effect/amendments/2025-10-17 https://compoundevidence.com/syntheses/lixisenatide-t2dm-effect/2024-11-01 https://compoundevidence.com/syntheses/lixisenatide-t2dm-effect/search-strategy/2024-11-01 https://compoundevidence.com/syntheses/lixisenatide-t2dm-effect/included-studies/2024-11-01 https://compoundevidence.com/syntheses/lixisenatide-t2dm-effect/summary-of-findings/2024-11-01 https://compoundevidence.com/syntheses/lixisenatide-t2dm-effect/amendments/2024-11-01 https://compoundevidence.com/syntheses/orforglipron-t2dm-effect/2026-02-15 https://compoundevidence.com/syntheses/orforglipron-t2dm-effect/search-strategy/2026-02-15 https://compoundevidence.com/syntheses/orforglipron-t2dm-effect/included-studies/2026-02-15 https://compoundevidence.com/syntheses/orforglipron-t2dm-effect/summary-of-findings/2026-02-15 https://compoundevidence.com/syntheses/orforglipron-t2dm-effect/amendments/2026-02-15 https://compoundevidence.com/syntheses/survodutide-obesity-effect/2026-09-05 https://compoundevidence.com/syntheses/survodutide-obesity-effect/search-strategy/2026-09-05 https://compoundevidence.com/syntheses/survodutide-obesity-effect/included-studies/2026-09-05 https://compoundevidence.com/syntheses/survodutide-obesity-effect/summary-of-findings/2026-09-05 https://compoundevidence.com/syntheses/survodutide-obesity-effect/amendments/2026-09-05 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-effect/2026-06-09 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-effect/search-strategy/2026-06-09 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-effect/included-studies/2026-06-09 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-effect/summary-of-findings/2026-06-09 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-effect/amendments/2026-06-09 https://compoundevidence.com/syntheses/exenatide-cvd-effect/2026-01-29 https://compoundevidence.com/syntheses/exenatide-cvd-effect/search-strategy/2026-01-29 https://compoundevidence.com/syntheses/exenatide-cvd-effect/included-studies/2026-01-29 https://compoundevidence.com/syntheses/exenatide-cvd-effect/summary-of-findings/2026-01-29 https://compoundevidence.com/syntheses/exenatide-cvd-effect/amendments/2026-01-29 https://compoundevidence.com/syntheses/liraglutide-obesity-effect/2026-08-20 https://compoundevidence.com/syntheses/liraglutide-obesity-effect/search-strategy/2026-08-20 https://compoundevidence.com/syntheses/liraglutide-obesity-effect/included-studies/2026-08-20 https://compoundevidence.com/syntheses/liraglutide-obesity-effect/summary-of-findings/2026-08-20 https://compoundevidence.com/syntheses/liraglutide-obesity-effect/amendments/2026-08-20 https://compoundevidence.com/syntheses/mazdutide-obesity-effect/2026-07-18 https://compoundevidence.com/syntheses/mazdutide-obesity-effect/search-strategy/2026-07-18 https://compoundevidence.com/syntheses/mazdutide-obesity-effect/included-studies/2026-07-18 https://compoundevidence.com/syntheses/mazdutide-obesity-effect/summary-of-findings/2026-07-18 https://compoundevidence.com/syntheses/mazdutide-obesity-effect/amendments/2026-07-18 https://compoundevidence.com/syntheses/mazdutide-t2dm-effect/2025-04-18 https://compoundevidence.com/syntheses/mazdutide-t2dm-effect/search-strategy/2025-04-18 https://compoundevidence.com/syntheses/mazdutide-t2dm-effect/included-studies/2025-04-18 https://compoundevidence.com/syntheses/mazdutide-t2dm-effect/summary-of-findings/2025-04-18 https://compoundevidence.com/syntheses/mazdutide-t2dm-effect/amendments/2025-04-18 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-effect/2026-01-18 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-effect/search-strategy/2026-01-18 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-effect/included-studies/2026-01-18 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-effect/summary-of-findings/2026-01-18 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-effect/amendments/2026-01-18 https://compoundevidence.com/syntheses/orforglipron-obesity-effect/2026-02-04 https://compoundevidence.com/syntheses/orforglipron-obesity-effect/search-strategy/2026-02-04 https://compoundevidence.com/syntheses/orforglipron-obesity-effect/included-studies/2026-02-04 https://compoundevidence.com/syntheses/orforglipron-obesity-effect/summary-of-findings/2026-02-04 https://compoundevidence.com/syntheses/orforglipron-obesity-effect/amendments/2026-02-04 https://compoundevidence.com/syntheses/teduglutide-ibd-effect/2025-06-28 https://compoundevidence.com/syntheses/teduglutide-ibd-effect/search-strategy/2025-06-28 https://compoundevidence.com/syntheses/teduglutide-ibd-effect/included-studies/2025-06-28 https://compoundevidence.com/syntheses/teduglutide-ibd-effect/summary-of-findings/2025-06-28 https://compoundevidence.com/syntheses/teduglutide-ibd-effect/amendments/2025-06-28 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-effect/2026-06-10 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-effect/search-strategy/2026-06-10 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-effect/included-studies/2026-06-10 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-effect/summary-of-findings/2026-06-10 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-effect/amendments/2026-06-10 https://compoundevidence.com/syntheses/cagrisema-t2dm-effect/2025-11-20 https://compoundevidence.com/syntheses/cagrisema-t2dm-effect/search-strategy/2025-11-20 https://compoundevidence.com/syntheses/cagrisema-t2dm-effect/included-studies/2025-11-20 https://compoundevidence.com/syntheses/cagrisema-t2dm-effect/summary-of-findings/2025-11-20 https://compoundevidence.com/syntheses/cagrisema-t2dm-effect/amendments/2025-11-20 https://compoundevidence.com/syntheses/cjc-1295-ghd-effect/2024-12-12 https://compoundevidence.com/syntheses/cjc-1295-ghd-effect/search-strategy/2024-12-12 https://compoundevidence.com/syntheses/cjc-1295-ghd-effect/included-studies/2024-12-12 https://compoundevidence.com/syntheses/cjc-1295-ghd-effect/summary-of-findings/2024-12-12 https://compoundevidence.com/syntheses/cjc-1295-ghd-effect/amendments/2024-12-12 https://compoundevidence.com/syntheses/dulaglutide-cvd-effect/2026-02-21 https://compoundevidence.com/syntheses/dulaglutide-cvd-effect/search-strategy/2026-02-21 https://compoundevidence.com/syntheses/dulaglutide-cvd-effect/included-studies/2026-02-21 https://compoundevidence.com/syntheses/dulaglutide-cvd-effect/summary-of-findings/2026-02-21 https://compoundevidence.com/syntheses/dulaglutide-cvd-effect/amendments/2026-02-21 https://compoundevidence.com/syntheses/ghk-cu-wound-healing-effect/2025-09-19 https://compoundevidence.com/syntheses/ghk-cu-wound-healing-effect/search-strategy/2025-09-19 https://compoundevidence.com/syntheses/ghk-cu-wound-healing-effect/included-studies/2025-09-19 https://compoundevidence.com/syntheses/ghk-cu-wound-healing-effect/summary-of-findings/2025-09-19 https://compoundevidence.com/syntheses/ghk-cu-wound-healing-effect/amendments/2025-09-19 https://compoundevidence.com/syntheses/gonadorelin-ghd-effect/2026-08-29 https://compoundevidence.com/syntheses/gonadorelin-ghd-effect/search-strategy/2026-08-29 https://compoundevidence.com/syntheses/gonadorelin-ghd-effect/included-studies/2026-08-29 https://compoundevidence.com/syntheses/gonadorelin-ghd-effect/summary-of-findings/2026-08-29 https://compoundevidence.com/syntheses/gonadorelin-ghd-effect/amendments/2026-08-29 https://compoundevidence.com/syntheses/kisspeptin-10-ghd-effect/2025-10-11 https://compoundevidence.com/syntheses/kisspeptin-10-ghd-effect/search-strategy/2025-10-11 https://compoundevidence.com/syntheses/kisspeptin-10-ghd-effect/included-studies/2025-10-11 https://compoundevidence.com/syntheses/kisspeptin-10-ghd-effect/summary-of-findings/2025-10-11 https://compoundevidence.com/syntheses/kisspeptin-10-ghd-effect/amendments/2025-10-11 https://compoundevidence.com/syntheses/larazotide-ibd-effect/2025-03-01 https://compoundevidence.com/syntheses/larazotide-ibd-effect/search-strategy/2025-03-01 https://compoundevidence.com/syntheses/larazotide-ibd-effect/included-studies/2025-03-01 https://compoundevidence.com/syntheses/larazotide-ibd-effect/summary-of-findings/2025-03-01 https://compoundevidence.com/syntheses/larazotide-ibd-effect/amendments/2025-03-01 https://compoundevidence.com/syntheses/liraglutide-t1dm-adjunct-effect/2025-09-04 https://compoundevidence.com/syntheses/liraglutide-t1dm-adjunct-effect/search-strategy/2025-09-04 https://compoundevidence.com/syntheses/liraglutide-t1dm-adjunct-effect/included-studies/2025-09-04 https://compoundevidence.com/syntheses/liraglutide-t1dm-adjunct-effect/summary-of-findings/2025-09-04 https://compoundevidence.com/syntheses/liraglutide-t1dm-adjunct-effect/amendments/2025-09-04 https://compoundevidence.com/syntheses/liraglutide-t2dm-effect/2026-04-20 https://compoundevidence.com/syntheses/liraglutide-t2dm-effect/search-strategy/2026-04-20 https://compoundevidence.com/syntheses/liraglutide-t2dm-effect/included-studies/2026-04-20 https://compoundevidence.com/syntheses/liraglutide-t2dm-effect/summary-of-findings/2026-04-20 https://compoundevidence.com/syntheses/liraglutide-t2dm-effect/amendments/2026-04-20 https://compoundevidence.com/syntheses/maridebart-cafraglutide-obesity-effect/2024-11-13 https://compoundevidence.com/syntheses/maridebart-cafraglutide-obesity-effect/search-strategy/2024-11-13 https://compoundevidence.com/syntheses/maridebart-cafraglutide-obesity-effect/included-studies/2024-11-13 https://compoundevidence.com/syntheses/maridebart-cafraglutide-obesity-effect/summary-of-findings/2024-11-13 https://compoundevidence.com/syntheses/maridebart-cafraglutide-obesity-effect/amendments/2024-11-13 https://compoundevidence.com/syntheses/oral-semaglutide-cvd-effect/2025-11-01 https://compoundevidence.com/syntheses/oral-semaglutide-cvd-effect/search-strategy/2025-11-01 https://compoundevidence.com/syntheses/oral-semaglutide-cvd-effect/included-studies/2025-11-01 https://compoundevidence.com/syntheses/oral-semaglutide-cvd-effect/summary-of-findings/2025-11-01 https://compoundevidence.com/syntheses/oral-semaglutide-cvd-effect/amendments/2025-11-01 https://compoundevidence.com/syntheses/petrelintide-obesity-effect/2026-01-19 https://compoundevidence.com/syntheses/petrelintide-obesity-effect/search-strategy/2026-01-19 https://compoundevidence.com/syntheses/petrelintide-obesity-effect/included-studies/2026-01-19 https://compoundevidence.com/syntheses/petrelintide-obesity-effect/summary-of-findings/2026-01-19 https://compoundevidence.com/syntheses/petrelintide-obesity-effect/amendments/2026-01-19 https://compoundevidence.com/syntheses/pt-141-sexual-dysfunction-effect/2026-02-04 https://compoundevidence.com/syntheses/pt-141-sexual-dysfunction-effect/search-strategy/2026-02-04 https://compoundevidence.com/syntheses/pt-141-sexual-dysfunction-effect/included-studies/2026-02-04 https://compoundevidence.com/syntheses/pt-141-sexual-dysfunction-effect/summary-of-findings/2026-02-04 https://compoundevidence.com/syntheses/pt-141-sexual-dysfunction-effect/amendments/2026-02-04 https://compoundevidence.com/syntheses/retatrutide-t2dm-effect/2026-05-10 https://compoundevidence.com/syntheses/retatrutide-t2dm-effect/search-strategy/2026-05-10 https://compoundevidence.com/syntheses/retatrutide-t2dm-effect/included-studies/2026-05-10 https://compoundevidence.com/syntheses/retatrutide-t2dm-effect/summary-of-findings/2026-05-10 https://compoundevidence.com/syntheses/retatrutide-t2dm-effect/amendments/2026-05-10 https://compoundevidence.com/syntheses/semaglutide-cvd-effect/2026-07-04 https://compoundevidence.com/syntheses/semaglutide-cvd-effect/search-strategy/2026-07-04 https://compoundevidence.com/syntheses/semaglutide-cvd-effect/included-studies/2026-07-04 https://compoundevidence.com/syntheses/semaglutide-cvd-effect/summary-of-findings/2026-07-04 https://compoundevidence.com/syntheses/semaglutide-cvd-effect/amendments/2026-07-04 https://compoundevidence.com/syntheses/semaglutide-hfpef-effect/2025-04-14 https://compoundevidence.com/syntheses/semaglutide-hfpef-effect/search-strategy/2025-04-14 https://compoundevidence.com/syntheses/semaglutide-hfpef-effect/included-studies/2025-04-14 https://compoundevidence.com/syntheses/semaglutide-hfpef-effect/summary-of-findings/2025-04-14 https://compoundevidence.com/syntheses/semaglutide-hfpef-effect/amendments/2025-04-14 https://compoundevidence.com/syntheses/semax-cognitive-effect/2024-12-26 https://compoundevidence.com/syntheses/semax-cognitive-effect/search-strategy/2024-12-26 https://compoundevidence.com/syntheses/semax-cognitive-effect/included-studies/2024-12-26 https://compoundevidence.com/syntheses/semax-cognitive-effect/summary-of-findings/2024-12-26 https://compoundevidence.com/syntheses/semax-cognitive-effect/amendments/2024-12-26 https://compoundevidence.com/syntheses/ss-31-mitochondrial-effect/2025-11-11 https://compoundevidence.com/syntheses/ss-31-mitochondrial-effect/search-strategy/2025-11-11 https://compoundevidence.com/syntheses/ss-31-mitochondrial-effect/included-studies/2025-11-11 https://compoundevidence.com/syntheses/ss-31-mitochondrial-effect/summary-of-findings/2025-11-11 https://compoundevidence.com/syntheses/ss-31-mitochondrial-effect/amendments/2025-11-11 https://compoundevidence.com/syntheses/tesamorelin-lipodystrophy-effect/2025-11-19 https://compoundevidence.com/syntheses/tesamorelin-lipodystrophy-effect/search-strategy/2025-11-19 https://compoundevidence.com/syntheses/tesamorelin-lipodystrophy-effect/included-studies/2025-11-19 https://compoundevidence.com/syntheses/tesamorelin-lipodystrophy-effect/summary-of-findings/2025-11-19 https://compoundevidence.com/syntheses/tesamorelin-lipodystrophy-effect/amendments/2025-11-19 https://compoundevidence.com/syntheses/tirzepatide-cvd-effect/2025-11-13 https://compoundevidence.com/syntheses/tirzepatide-cvd-effect/search-strategy/2025-11-13 https://compoundevidence.com/syntheses/tirzepatide-cvd-effect/included-studies/2025-11-13 https://compoundevidence.com/syntheses/tirzepatide-cvd-effect/summary-of-findings/2025-11-13 https://compoundevidence.com/syntheses/tirzepatide-cvd-effect/amendments/2025-11-13 https://compoundevidence.com/syntheses/tirzepatide-osa-effect/2025-09-27 https://compoundevidence.com/syntheses/tirzepatide-osa-effect/search-strategy/2025-09-27 https://compoundevidence.com/syntheses/tirzepatide-osa-effect/included-studies/2025-09-27 https://compoundevidence.com/syntheses/tirzepatide-osa-effect/summary-of-findings/2025-09-27 https://compoundevidence.com/syntheses/tirzepatide-osa-effect/amendments/2025-09-27 https://compoundevidence.com/syntheses/tirzepatide-obesity-tolerability/2026-04-26 https://compoundevidence.com/syntheses/tirzepatide-obesity-tolerability/search-strategy/2026-04-26 https://compoundevidence.com/syntheses/tirzepatide-obesity-tolerability/included-studies/2026-04-26 https://compoundevidence.com/syntheses/tirzepatide-obesity-tolerability/summary-of-findings/2026-04-26 https://compoundevidence.com/syntheses/tirzepatide-obesity-tolerability/amendments/2026-04-26 https://compoundevidence.com/syntheses/semaglutide-obesity-tolerability/2025-05-08 https://compoundevidence.com/syntheses/semaglutide-obesity-tolerability/search-strategy/2025-05-08 https://compoundevidence.com/syntheses/semaglutide-obesity-tolerability/included-studies/2025-05-08 https://compoundevidence.com/syntheses/semaglutide-obesity-tolerability/summary-of-findings/2025-05-08 https://compoundevidence.com/syntheses/semaglutide-obesity-tolerability/amendments/2025-05-08 https://compoundevidence.com/syntheses/dulaglutide-t2dm-tolerability/2026-05-21 https://compoundevidence.com/syntheses/dulaglutide-t2dm-tolerability/search-strategy/2026-05-21 https://compoundevidence.com/syntheses/dulaglutide-t2dm-tolerability/included-studies/2026-05-21 https://compoundevidence.com/syntheses/dulaglutide-t2dm-tolerability/summary-of-findings/2026-05-21 https://compoundevidence.com/syntheses/dulaglutide-t2dm-tolerability/amendments/2026-05-21 https://compoundevidence.com/syntheses/semaglutide-t2dm-tolerability/2026-06-18 https://compoundevidence.com/syntheses/semaglutide-t2dm-tolerability/search-strategy/2026-06-18 https://compoundevidence.com/syntheses/semaglutide-t2dm-tolerability/included-studies/2026-06-18 https://compoundevidence.com/syntheses/semaglutide-t2dm-tolerability/summary-of-findings/2026-06-18 https://compoundevidence.com/syntheses/semaglutide-t2dm-tolerability/amendments/2026-06-18 https://compoundevidence.com/syntheses/tirzepatide-t2dm-tolerability/2025-10-09 https://compoundevidence.com/syntheses/tirzepatide-t2dm-tolerability/search-strategy/2025-10-09 https://compoundevidence.com/syntheses/tirzepatide-t2dm-tolerability/included-studies/2025-10-09 https://compoundevidence.com/syntheses/tirzepatide-t2dm-tolerability/summary-of-findings/2025-10-09 https://compoundevidence.com/syntheses/tirzepatide-t2dm-tolerability/amendments/2025-10-09 https://compoundevidence.com/syntheses/exenatide-t2dm-tolerability/2025-01-31 https://compoundevidence.com/syntheses/exenatide-t2dm-tolerability/search-strategy/2025-01-31 https://compoundevidence.com/syntheses/exenatide-t2dm-tolerability/included-studies/2025-01-31 https://compoundevidence.com/syntheses/exenatide-t2dm-tolerability/summary-of-findings/2025-01-31 https://compoundevidence.com/syntheses/exenatide-t2dm-tolerability/amendments/2025-01-31 https://compoundevidence.com/syntheses/retatrutide-obesity-tolerability/2025-03-10 https://compoundevidence.com/syntheses/retatrutide-obesity-tolerability/search-strategy/2025-03-10 https://compoundevidence.com/syntheses/retatrutide-obesity-tolerability/included-studies/2025-03-10 https://compoundevidence.com/syntheses/retatrutide-obesity-tolerability/summary-of-findings/2025-03-10 https://compoundevidence.com/syntheses/retatrutide-obesity-tolerability/amendments/2025-03-10 https://compoundevidence.com/syntheses/cagrisema-obesity-tolerability/2026-01-13 https://compoundevidence.com/syntheses/cagrisema-obesity-tolerability/search-strategy/2026-01-13 https://compoundevidence.com/syntheses/cagrisema-obesity-tolerability/included-studies/2026-01-13 https://compoundevidence.com/syntheses/cagrisema-obesity-tolerability/summary-of-findings/2026-01-13 https://compoundevidence.com/syntheses/cagrisema-obesity-tolerability/amendments/2026-01-13 https://compoundevidence.com/syntheses/lixisenatide-t2dm-tolerability/2026-05-31 https://compoundevidence.com/syntheses/lixisenatide-t2dm-tolerability/search-strategy/2026-05-31 https://compoundevidence.com/syntheses/lixisenatide-t2dm-tolerability/included-studies/2026-05-31 https://compoundevidence.com/syntheses/lixisenatide-t2dm-tolerability/summary-of-findings/2026-05-31 https://compoundevidence.com/syntheses/lixisenatide-t2dm-tolerability/amendments/2026-05-31 https://compoundevidence.com/syntheses/orforglipron-t2dm-tolerability/2026-05-05 https://compoundevidence.com/syntheses/orforglipron-t2dm-tolerability/search-strategy/2026-05-05 https://compoundevidence.com/syntheses/orforglipron-t2dm-tolerability/included-studies/2026-05-05 https://compoundevidence.com/syntheses/orforglipron-t2dm-tolerability/summary-of-findings/2026-05-05 https://compoundevidence.com/syntheses/orforglipron-t2dm-tolerability/amendments/2026-05-05 https://compoundevidence.com/syntheses/survodutide-obesity-tolerability/2025-07-15 https://compoundevidence.com/syntheses/survodutide-obesity-tolerability/search-strategy/2025-07-15 https://compoundevidence.com/syntheses/survodutide-obesity-tolerability/included-studies/2025-07-15 https://compoundevidence.com/syntheses/survodutide-obesity-tolerability/summary-of-findings/2025-07-15 https://compoundevidence.com/syntheses/survodutide-obesity-tolerability/amendments/2025-07-15 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-tolerability/2025-03-30 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-tolerability/search-strategy/2025-03-30 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-tolerability/included-studies/2025-03-30 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-tolerability/summary-of-findings/2025-03-30 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-tolerability/amendments/2025-03-30 https://compoundevidence.com/syntheses/exenatide-cvd-tolerability/2026-01-07 https://compoundevidence.com/syntheses/exenatide-cvd-tolerability/search-strategy/2026-01-07 https://compoundevidence.com/syntheses/exenatide-cvd-tolerability/included-studies/2026-01-07 https://compoundevidence.com/syntheses/exenatide-cvd-tolerability/summary-of-findings/2026-01-07 https://compoundevidence.com/syntheses/exenatide-cvd-tolerability/amendments/2026-01-07 https://compoundevidence.com/syntheses/liraglutide-obesity-tolerability/2026-03-11 https://compoundevidence.com/syntheses/liraglutide-obesity-tolerability/search-strategy/2026-03-11 https://compoundevidence.com/syntheses/liraglutide-obesity-tolerability/included-studies/2026-03-11 https://compoundevidence.com/syntheses/liraglutide-obesity-tolerability/summary-of-findings/2026-03-11 https://compoundevidence.com/syntheses/liraglutide-obesity-tolerability/amendments/2026-03-11 https://compoundevidence.com/syntheses/mazdutide-obesity-tolerability/2026-05-18 https://compoundevidence.com/syntheses/mazdutide-obesity-tolerability/search-strategy/2026-05-18 https://compoundevidence.com/syntheses/mazdutide-obesity-tolerability/included-studies/2026-05-18 https://compoundevidence.com/syntheses/mazdutide-obesity-tolerability/summary-of-findings/2026-05-18 https://compoundevidence.com/syntheses/mazdutide-obesity-tolerability/amendments/2026-05-18 https://compoundevidence.com/syntheses/mazdutide-t2dm-tolerability/2026-06-02 https://compoundevidence.com/syntheses/mazdutide-t2dm-tolerability/search-strategy/2026-06-02 https://compoundevidence.com/syntheses/mazdutide-t2dm-tolerability/included-studies/2026-06-02 https://compoundevidence.com/syntheses/mazdutide-t2dm-tolerability/summary-of-findings/2026-06-02 https://compoundevidence.com/syntheses/mazdutide-t2dm-tolerability/amendments/2026-06-02 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-tolerability/2026-05-19 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-tolerability/search-strategy/2026-05-19 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-tolerability/included-studies/2026-05-19 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-tolerability/summary-of-findings/2026-05-19 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-tolerability/amendments/2026-05-19 https://compoundevidence.com/syntheses/orforglipron-obesity-tolerability/2025-06-16 https://compoundevidence.com/syntheses/orforglipron-obesity-tolerability/search-strategy/2025-06-16 https://compoundevidence.com/syntheses/orforglipron-obesity-tolerability/included-studies/2025-06-16 https://compoundevidence.com/syntheses/orforglipron-obesity-tolerability/summary-of-findings/2025-06-16 https://compoundevidence.com/syntheses/orforglipron-obesity-tolerability/amendments/2025-06-16 https://compoundevidence.com/syntheses/teduglutide-ibd-tolerability/2026-09-07 https://compoundevidence.com/syntheses/teduglutide-ibd-tolerability/search-strategy/2026-09-07 https://compoundevidence.com/syntheses/teduglutide-ibd-tolerability/included-studies/2026-09-07 https://compoundevidence.com/syntheses/teduglutide-ibd-tolerability/summary-of-findings/2026-09-07 https://compoundevidence.com/syntheses/teduglutide-ibd-tolerability/amendments/2026-09-07 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-tolerability/2025-07-24 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-tolerability/search-strategy/2025-07-24 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-tolerability/included-studies/2025-07-24 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-tolerability/summary-of-findings/2025-07-24 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-tolerability/amendments/2025-07-24 https://compoundevidence.com/syntheses/cagrisema-t2dm-tolerability/2025-06-12 https://compoundevidence.com/syntheses/cagrisema-t2dm-tolerability/search-strategy/2025-06-12 https://compoundevidence.com/syntheses/cagrisema-t2dm-tolerability/included-studies/2025-06-12 https://compoundevidence.com/syntheses/cagrisema-t2dm-tolerability/summary-of-findings/2025-06-12 https://compoundevidence.com/syntheses/cagrisema-t2dm-tolerability/amendments/2025-06-12 https://compoundevidence.com/syntheses/cjc-1295-ghd-tolerability/2026-04-17 https://compoundevidence.com/syntheses/cjc-1295-ghd-tolerability/search-strategy/2026-04-17 https://compoundevidence.com/syntheses/cjc-1295-ghd-tolerability/included-studies/2026-04-17 https://compoundevidence.com/syntheses/cjc-1295-ghd-tolerability/summary-of-findings/2026-04-17 https://compoundevidence.com/syntheses/cjc-1295-ghd-tolerability/amendments/2026-04-17 https://compoundevidence.com/syntheses/dulaglutide-cvd-tolerability/2024-11-27 https://compoundevidence.com/syntheses/dulaglutide-cvd-tolerability/search-strategy/2024-11-27 https://compoundevidence.com/syntheses/dulaglutide-cvd-tolerability/included-studies/2024-11-27 https://compoundevidence.com/syntheses/dulaglutide-cvd-tolerability/summary-of-findings/2024-11-27 https://compoundevidence.com/syntheses/dulaglutide-cvd-tolerability/amendments/2024-11-27 https://compoundevidence.com/syntheses/ghk-cu-wound-healing-tolerability/2025-12-02 https://compoundevidence.com/syntheses/ghk-cu-wound-healing-tolerability/search-strategy/2025-12-02 https://compoundevidence.com/syntheses/ghk-cu-wound-healing-tolerability/included-studies/2025-12-02 https://compoundevidence.com/syntheses/ghk-cu-wound-healing-tolerability/summary-of-findings/2025-12-02 https://compoundevidence.com/syntheses/ghk-cu-wound-healing-tolerability/amendments/2025-12-02 https://compoundevidence.com/syntheses/gonadorelin-ghd-tolerability/2026-01-23 https://compoundevidence.com/syntheses/gonadorelin-ghd-tolerability/search-strategy/2026-01-23 https://compoundevidence.com/syntheses/gonadorelin-ghd-tolerability/included-studies/2026-01-23 https://compoundevidence.com/syntheses/gonadorelin-ghd-tolerability/summary-of-findings/2026-01-23 https://compoundevidence.com/syntheses/gonadorelin-ghd-tolerability/amendments/2026-01-23 https://compoundevidence.com/syntheses/kisspeptin-10-ghd-tolerability/2025-06-26 https://compoundevidence.com/syntheses/kisspeptin-10-ghd-tolerability/search-strategy/2025-06-26 https://compoundevidence.com/syntheses/kisspeptin-10-ghd-tolerability/included-studies/2025-06-26 https://compoundevidence.com/syntheses/kisspeptin-10-ghd-tolerability/summary-of-findings/2025-06-26 https://compoundevidence.com/syntheses/kisspeptin-10-ghd-tolerability/amendments/2025-06-26 https://compoundevidence.com/syntheses/larazotide-ibd-tolerability/2026-02-19 https://compoundevidence.com/syntheses/larazotide-ibd-tolerability/search-strategy/2026-02-19 https://compoundevidence.com/syntheses/larazotide-ibd-tolerability/included-studies/2026-02-19 https://compoundevidence.com/syntheses/larazotide-ibd-tolerability/summary-of-findings/2026-02-19 https://compoundevidence.com/syntheses/larazotide-ibd-tolerability/amendments/2026-02-19 https://compoundevidence.com/syntheses/liraglutide-t1dm-adjunct-tolerability/2026-05-07 https://compoundevidence.com/syntheses/liraglutide-t1dm-adjunct-tolerability/search-strategy/2026-05-07 https://compoundevidence.com/syntheses/liraglutide-t1dm-adjunct-tolerability/included-studies/2026-05-07 https://compoundevidence.com/syntheses/liraglutide-t1dm-adjunct-tolerability/summary-of-findings/2026-05-07 https://compoundevidence.com/syntheses/liraglutide-t1dm-adjunct-tolerability/amendments/2026-05-07 https://compoundevidence.com/syntheses/liraglutide-t2dm-tolerability/2026-03-03 https://compoundevidence.com/syntheses/liraglutide-t2dm-tolerability/search-strategy/2026-03-03 https://compoundevidence.com/syntheses/liraglutide-t2dm-tolerability/included-studies/2026-03-03 https://compoundevidence.com/syntheses/liraglutide-t2dm-tolerability/summary-of-findings/2026-03-03 https://compoundevidence.com/syntheses/liraglutide-t2dm-tolerability/amendments/2026-03-03 https://compoundevidence.com/syntheses/maridebart-cafraglutide-obesity-tolerability/2025-01-21 https://compoundevidence.com/syntheses/maridebart-cafraglutide-obesity-tolerability/search-strategy/2025-01-21 https://compoundevidence.com/syntheses/maridebart-cafraglutide-obesity-tolerability/included-studies/2025-01-21 https://compoundevidence.com/syntheses/maridebart-cafraglutide-obesity-tolerability/summary-of-findings/2025-01-21 https://compoundevidence.com/syntheses/maridebart-cafraglutide-obesity-tolerability/amendments/2025-01-21 https://compoundevidence.com/syntheses/oral-semaglutide-cvd-tolerability/2026-03-02 https://compoundevidence.com/syntheses/oral-semaglutide-cvd-tolerability/search-strategy/2026-03-02 https://compoundevidence.com/syntheses/oral-semaglutide-cvd-tolerability/included-studies/2026-03-02 https://compoundevidence.com/syntheses/oral-semaglutide-cvd-tolerability/summary-of-findings/2026-03-02 https://compoundevidence.com/syntheses/oral-semaglutide-cvd-tolerability/amendments/2026-03-02 https://compoundevidence.com/syntheses/petrelintide-obesity-tolerability/2026-02-11 https://compoundevidence.com/syntheses/petrelintide-obesity-tolerability/search-strategy/2026-02-11 https://compoundevidence.com/syntheses/petrelintide-obesity-tolerability/included-studies/2026-02-11 https://compoundevidence.com/syntheses/petrelintide-obesity-tolerability/summary-of-findings/2026-02-11 https://compoundevidence.com/syntheses/petrelintide-obesity-tolerability/amendments/2026-02-11 https://compoundevidence.com/syntheses/pt-141-sexual-dysfunction-tolerability/2026-06-05 https://compoundevidence.com/syntheses/pt-141-sexual-dysfunction-tolerability/search-strategy/2026-06-05 https://compoundevidence.com/syntheses/pt-141-sexual-dysfunction-tolerability/included-studies/2026-06-05 https://compoundevidence.com/syntheses/pt-141-sexual-dysfunction-tolerability/summary-of-findings/2026-06-05 https://compoundevidence.com/syntheses/pt-141-sexual-dysfunction-tolerability/amendments/2026-06-05 https://compoundevidence.com/syntheses/retatrutide-t2dm-tolerability/2026-06-12 https://compoundevidence.com/syntheses/retatrutide-t2dm-tolerability/search-strategy/2026-06-12 https://compoundevidence.com/syntheses/retatrutide-t2dm-tolerability/included-studies/2026-06-12 https://compoundevidence.com/syntheses/retatrutide-t2dm-tolerability/summary-of-findings/2026-06-12 https://compoundevidence.com/syntheses/retatrutide-t2dm-tolerability/amendments/2026-06-12 https://compoundevidence.com/syntheses/semaglutide-cvd-tolerability/2026-04-14 https://compoundevidence.com/syntheses/semaglutide-cvd-tolerability/search-strategy/2026-04-14 https://compoundevidence.com/syntheses/semaglutide-cvd-tolerability/included-studies/2026-04-14 https://compoundevidence.com/syntheses/semaglutide-cvd-tolerability/summary-of-findings/2026-04-14 https://compoundevidence.com/syntheses/semaglutide-cvd-tolerability/amendments/2026-04-14 https://compoundevidence.com/syntheses/semaglutide-hfpef-tolerability/2026-01-23 https://compoundevidence.com/syntheses/semaglutide-hfpef-tolerability/search-strategy/2026-01-23 https://compoundevidence.com/syntheses/semaglutide-hfpef-tolerability/included-studies/2026-01-23 https://compoundevidence.com/syntheses/semaglutide-hfpef-tolerability/summary-of-findings/2026-01-23 https://compoundevidence.com/syntheses/semaglutide-hfpef-tolerability/amendments/2026-01-23 https://compoundevidence.com/syntheses/semax-cognitive-tolerability/2025-01-11 https://compoundevidence.com/syntheses/semax-cognitive-tolerability/search-strategy/2025-01-11 https://compoundevidence.com/syntheses/semax-cognitive-tolerability/included-studies/2025-01-11 https://compoundevidence.com/syntheses/semax-cognitive-tolerability/summary-of-findings/2025-01-11 https://compoundevidence.com/syntheses/semax-cognitive-tolerability/amendments/2025-01-11 https://compoundevidence.com/syntheses/ss-31-mitochondrial-tolerability/2025-05-14 https://compoundevidence.com/syntheses/ss-31-mitochondrial-tolerability/search-strategy/2025-05-14 https://compoundevidence.com/syntheses/ss-31-mitochondrial-tolerability/included-studies/2025-05-14 https://compoundevidence.com/syntheses/ss-31-mitochondrial-tolerability/summary-of-findings/2025-05-14 https://compoundevidence.com/syntheses/ss-31-mitochondrial-tolerability/amendments/2025-05-14 https://compoundevidence.com/syntheses/tesamorelin-lipodystrophy-tolerability/2024-12-08 https://compoundevidence.com/syntheses/tesamorelin-lipodystrophy-tolerability/search-strategy/2024-12-08 https://compoundevidence.com/syntheses/tesamorelin-lipodystrophy-tolerability/included-studies/2024-12-08 https://compoundevidence.com/syntheses/tesamorelin-lipodystrophy-tolerability/summary-of-findings/2024-12-08 https://compoundevidence.com/syntheses/tesamorelin-lipodystrophy-tolerability/amendments/2024-12-08 https://compoundevidence.com/syntheses/tirzepatide-cvd-tolerability/2026-05-22 https://compoundevidence.com/syntheses/tirzepatide-cvd-tolerability/search-strategy/2026-05-22 https://compoundevidence.com/syntheses/tirzepatide-cvd-tolerability/included-studies/2026-05-22 https://compoundevidence.com/syntheses/tirzepatide-cvd-tolerability/summary-of-findings/2026-05-22 https://compoundevidence.com/syntheses/tirzepatide-cvd-tolerability/amendments/2026-05-22 https://compoundevidence.com/syntheses/tirzepatide-osa-tolerability/2025-06-27 https://compoundevidence.com/syntheses/tirzepatide-osa-tolerability/search-strategy/2025-06-27 https://compoundevidence.com/syntheses/tirzepatide-osa-tolerability/included-studies/2025-06-27 https://compoundevidence.com/syntheses/tirzepatide-osa-tolerability/summary-of-findings/2025-06-27 https://compoundevidence.com/syntheses/tirzepatide-osa-tolerability/amendments/2025-06-27 https://compoundevidence.com/syntheses/tirzepatide-obesity-durability/2026-04-15 https://compoundevidence.com/syntheses/tirzepatide-obesity-durability/search-strategy/2026-04-15 https://compoundevidence.com/syntheses/tirzepatide-obesity-durability/included-studies/2026-04-15 https://compoundevidence.com/syntheses/tirzepatide-obesity-durability/summary-of-findings/2026-04-15 https://compoundevidence.com/syntheses/tirzepatide-obesity-durability/amendments/2026-04-15 https://compoundevidence.com/syntheses/semaglutide-obesity-durability/2025-08-01 https://compoundevidence.com/syntheses/semaglutide-obesity-durability/search-strategy/2025-08-01 https://compoundevidence.com/syntheses/semaglutide-obesity-durability/included-studies/2025-08-01 https://compoundevidence.com/syntheses/semaglutide-obesity-durability/summary-of-findings/2025-08-01 https://compoundevidence.com/syntheses/semaglutide-obesity-durability/amendments/2025-08-01 https://compoundevidence.com/syntheses/dulaglutide-t2dm-durability/2026-05-12 https://compoundevidence.com/syntheses/dulaglutide-t2dm-durability/search-strategy/2026-05-12 https://compoundevidence.com/syntheses/dulaglutide-t2dm-durability/included-studies/2026-05-12 https://compoundevidence.com/syntheses/dulaglutide-t2dm-durability/summary-of-findings/2026-05-12 https://compoundevidence.com/syntheses/dulaglutide-t2dm-durability/amendments/2026-05-12 https://compoundevidence.com/syntheses/semaglutide-t2dm-durability/2026-02-18 https://compoundevidence.com/syntheses/semaglutide-t2dm-durability/search-strategy/2026-02-18 https://compoundevidence.com/syntheses/semaglutide-t2dm-durability/included-studies/2026-02-18 https://compoundevidence.com/syntheses/semaglutide-t2dm-durability/summary-of-findings/2026-02-18 https://compoundevidence.com/syntheses/semaglutide-t2dm-durability/amendments/2026-02-18 https://compoundevidence.com/syntheses/tirzepatide-t2dm-durability/2026-05-16 https://compoundevidence.com/syntheses/tirzepatide-t2dm-durability/search-strategy/2026-05-16 https://compoundevidence.com/syntheses/tirzepatide-t2dm-durability/included-studies/2026-05-16 https://compoundevidence.com/syntheses/tirzepatide-t2dm-durability/summary-of-findings/2026-05-16 https://compoundevidence.com/syntheses/tirzepatide-t2dm-durability/amendments/2026-05-16 https://compoundevidence.com/syntheses/exenatide-t2dm-durability/2026-02-27 https://compoundevidence.com/syntheses/exenatide-t2dm-durability/search-strategy/2026-02-27 https://compoundevidence.com/syntheses/exenatide-t2dm-durability/included-studies/2026-02-27 https://compoundevidence.com/syntheses/exenatide-t2dm-durability/summary-of-findings/2026-02-27 https://compoundevidence.com/syntheses/exenatide-t2dm-durability/amendments/2026-02-27 https://compoundevidence.com/syntheses/retatrutide-obesity-durability/2025-11-16 https://compoundevidence.com/syntheses/retatrutide-obesity-durability/search-strategy/2025-11-16 https://compoundevidence.com/syntheses/retatrutide-obesity-durability/included-studies/2025-11-16 https://compoundevidence.com/syntheses/retatrutide-obesity-durability/summary-of-findings/2025-11-16 https://compoundevidence.com/syntheses/retatrutide-obesity-durability/amendments/2025-11-16 https://compoundevidence.com/syntheses/cagrisema-obesity-durability/2026-03-13 https://compoundevidence.com/syntheses/cagrisema-obesity-durability/search-strategy/2026-03-13 https://compoundevidence.com/syntheses/cagrisema-obesity-durability/included-studies/2026-03-13 https://compoundevidence.com/syntheses/cagrisema-obesity-durability/summary-of-findings/2026-03-13 https://compoundevidence.com/syntheses/cagrisema-obesity-durability/amendments/2026-03-13 https://compoundevidence.com/syntheses/lixisenatide-t2dm-durability/2026-02-03 https://compoundevidence.com/syntheses/lixisenatide-t2dm-durability/search-strategy/2026-02-03 https://compoundevidence.com/syntheses/lixisenatide-t2dm-durability/included-studies/2026-02-03 https://compoundevidence.com/syntheses/lixisenatide-t2dm-durability/summary-of-findings/2026-02-03 https://compoundevidence.com/syntheses/lixisenatide-t2dm-durability/amendments/2026-02-03 https://compoundevidence.com/syntheses/orforglipron-t2dm-durability/2026-04-21 https://compoundevidence.com/syntheses/orforglipron-t2dm-durability/search-strategy/2026-04-21 https://compoundevidence.com/syntheses/orforglipron-t2dm-durability/included-studies/2026-04-21 https://compoundevidence.com/syntheses/orforglipron-t2dm-durability/summary-of-findings/2026-04-21 https://compoundevidence.com/syntheses/orforglipron-t2dm-durability/amendments/2026-04-21 https://compoundevidence.com/syntheses/survodutide-obesity-durability/2026-05-10 https://compoundevidence.com/syntheses/survodutide-obesity-durability/search-strategy/2026-05-10 https://compoundevidence.com/syntheses/survodutide-obesity-durability/included-studies/2026-05-10 https://compoundevidence.com/syntheses/survodutide-obesity-durability/summary-of-findings/2026-05-10 https://compoundevidence.com/syntheses/survodutide-obesity-durability/amendments/2026-05-10 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-durability/2026-08-26 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-durability/search-strategy/2026-08-26 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-durability/included-studies/2026-08-26 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-durability/summary-of-findings/2026-08-26 https://compoundevidence.com/syntheses/thymosin-alpha-1-immune-support-durability/amendments/2026-08-26 https://compoundevidence.com/syntheses/exenatide-cvd-durability/2026-06-25 https://compoundevidence.com/syntheses/exenatide-cvd-durability/search-strategy/2026-06-25 https://compoundevidence.com/syntheses/exenatide-cvd-durability/included-studies/2026-06-25 https://compoundevidence.com/syntheses/exenatide-cvd-durability/summary-of-findings/2026-06-25 https://compoundevidence.com/syntheses/exenatide-cvd-durability/amendments/2026-06-25 https://compoundevidence.com/syntheses/liraglutide-obesity-durability/2025-11-15 https://compoundevidence.com/syntheses/liraglutide-obesity-durability/search-strategy/2025-11-15 https://compoundevidence.com/syntheses/liraglutide-obesity-durability/included-studies/2025-11-15 https://compoundevidence.com/syntheses/liraglutide-obesity-durability/summary-of-findings/2025-11-15 https://compoundevidence.com/syntheses/liraglutide-obesity-durability/amendments/2025-11-15 https://compoundevidence.com/syntheses/mazdutide-obesity-durability/2025-08-18 https://compoundevidence.com/syntheses/mazdutide-obesity-durability/search-strategy/2025-08-18 https://compoundevidence.com/syntheses/mazdutide-obesity-durability/included-studies/2025-08-18 https://compoundevidence.com/syntheses/mazdutide-obesity-durability/summary-of-findings/2025-08-18 https://compoundevidence.com/syntheses/mazdutide-obesity-durability/amendments/2025-08-18 https://compoundevidence.com/syntheses/mazdutide-t2dm-durability/2025-02-13 https://compoundevidence.com/syntheses/mazdutide-t2dm-durability/search-strategy/2025-02-13 https://compoundevidence.com/syntheses/mazdutide-t2dm-durability/included-studies/2025-02-13 https://compoundevidence.com/syntheses/mazdutide-t2dm-durability/summary-of-findings/2025-02-13 https://compoundevidence.com/syntheses/mazdutide-t2dm-durability/amendments/2025-02-13 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-durability/2025-08-06 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-durability/search-strategy/2025-08-06 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-durability/included-studies/2025-08-06 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-durability/summary-of-findings/2025-08-06 https://compoundevidence.com/syntheses/oral-semaglutide-t2dm-durability/amendments/2025-08-06 https://compoundevidence.com/syntheses/orforglipron-obesity-durability/2024-11-09 https://compoundevidence.com/syntheses/orforglipron-obesity-durability/search-strategy/2024-11-09 https://compoundevidence.com/syntheses/orforglipron-obesity-durability/included-studies/2024-11-09 https://compoundevidence.com/syntheses/orforglipron-obesity-durability/summary-of-findings/2024-11-09 https://compoundevidence.com/syntheses/orforglipron-obesity-durability/amendments/2024-11-09 https://compoundevidence.com/syntheses/teduglutide-ibd-durability/2025-11-22 https://compoundevidence.com/syntheses/teduglutide-ibd-durability/search-strategy/2025-11-22 https://compoundevidence.com/syntheses/teduglutide-ibd-durability/included-studies/2025-11-22 https://compoundevidence.com/syntheses/teduglutide-ibd-durability/summary-of-findings/2025-11-22 https://compoundevidence.com/syntheses/teduglutide-ibd-durability/amendments/2025-11-22 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-durability/2026-03-10 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-durability/search-strategy/2026-03-10 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-durability/included-studies/2026-03-10 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-durability/summary-of-findings/2026-03-10 https://compoundevidence.com/syntheses/thymosin-beta-4-wound-healing-durability/amendments/2026-03-10 https://compoundevidence.com/syntheses/cagrisema-t2dm-durability/2026-05-02 https://compoundevidence.com/syntheses/cagrisema-t2dm-durability/search-strategy/2026-05-02 https://compoundevidence.com/syntheses/cagrisema-t2dm-durability/included-studies/2026-05-02 https://compoundevidence.com/syntheses/cagrisema-t2dm-durability/summary-of-findings/2026-05-02 https://compoundevidence.com/syntheses/cagrisema-t2dm-durability/amendments/2026-05-02 https://compoundevidence.com/syntheses/cjc-1295-ghd-durability/2026-03-07 https://compoundevidence.com/syntheses/cjc-1295-ghd-durability/search-strategy/2026-03-07 https://compoundevidence.com/syntheses/cjc-1295-ghd-durability/included-studies/2026-03-07 https://compoundevidence.com/syntheses/cjc-1295-ghd-durability/summary-of-findings/2026-03-07 https://compoundevidence.com/syntheses/cjc-1295-ghd-durability/amendments/2026-03-07